Less Time in the Infusion Chair: What Wearable Cancer Drug Injectors Could Mean
For many cancer patients, treatment is not only about the medicine itself. It is also about the time, energy, travel, waiting, and stress that come with each appointment.
A person may need to arrange a ride, take time off work, ask a caregiver to come along, sit in an infusion chair for hours, and then travel home tired. For people who receive cancer treatment again and again, this routine can become a major part of life.
That is why a recent FDA approval is getting attention.
In July 2026, the U.S. Food and Drug Administration approved a new subcutaneous form of isatuximab-irfc for certain multiple myeloma treatment regimens. The drug can be given under the skin using the CirCLIQ on-body delivery system, also called an on-body injector, or by manual injection with a syringe and infusion set. The FDA lists the recommended dose as 1,400 mg given subcutaneously with approved treatment combinations for multiple myeloma.
Reuters reported that this is the first FDA-approved cancer drug that can be delivered through an on-body injector attached to the skin. Reuters also reported that the device may reduce treatment time for patients with multiple myeloma, with a median injection time of about 13 minutes compared with IV infusions that can take up to three hours.
This does not mean every cancer patient will use a wearable injector. It does not mean all infusion visits are going away. But it does show an important trend in cancer care: researchers and drug companies are looking for ways to make treatment less burdensome for patients, caregivers, and clinics.
What Is Multiple Myeloma?
Multiple myeloma is a type of blood cancer. It starts in plasma cells, which are a kind of white blood cell found in the bone marrow. Healthy plasma cells help the body fight infection by making antibodies. In multiple myeloma, cancerous plasma cells can crowd out healthy blood cells and cause problems such as bone pain, anemia, infections, kidney issues, and fatigue.
Multiple myeloma is often treated with a combination of medicines. These may include targeted therapy, immunotherapy, steroids, chemotherapy, and sometimes stem cell transplant. Treatment plans vary based on a person’s age, overall health, prior treatments, kidney function, symptoms, and whether the cancer is newly diagnosed or has returned.
What Is Sarclisa?
Sarclisa is the brand name for isatuximab-irfc. It is a monoclonal antibody, which means it is a lab-made immune system protein. The American Cancer Society explains that isatuximab attaches to a protein called CD38 on myeloma cells and is used with other myeloma drugs in certain treatment settings.
In simple terms, Sarclisa helps the immune system recognize and attack myeloma cells. Until now, many patients received this medicine through an IV infusion. IV treatment can take time because the drug enters the body through a vein and patients may need monitoring before, during, and after treatment.
The newly approved subcutaneous version is given under the skin instead of through a vein. The on-body injector is attached to the skin and delivers the medicine over a shorter period of time.
What Is a Wearable Cancer Drug Injector?
A wearable cancer drug injector is a device placed on the body to deliver medicine under the skin. It is sometimes called an on-body injector. The device is usually attached by a trained health care professional.
For patients, the idea may sound similar to other wearable medical devices, but cancer medicines require careful handling and monitoring. This is not something patients should use on their own unless their oncology team gives clear instructions and support.
The goal is not just convenience. The goal is to safely deliver treatment in a way that may reduce time in the clinic, lower the need for long IV infusions, and make repeated treatment visits easier to manage.
Why Less Time in the Infusion Chair Matters
When people talk about cancer treatment, they often focus on whether a drug works. That matters most. But treatment burden matters too.
Treatment burden means everything a patient and caregiver must do to receive care. This may include:
Traveling to the cancer center
Finding parking
Checking in
Waiting for lab work
Waiting for the medicine to be prepared
Sitting through a long infusion
Managing side effects
Missing work or family responsibilities
Arranging childcare
Depending on a caregiver for transportation
For some people, a shorter treatment visit can make a big difference. It may mean less fatigue, less time away from home, fewer caregiver hours, and more flexibility in daily life.
This can be especially important for multiple myeloma patients because treatment often continues over a long period of time. Even small time savings can add up over months or years.
What Could This Mean for Caregivers?
Caregivers are often the hidden support system behind cancer treatment. They may drive patients to appointments, sit beside them during infusions, track medications, ask questions, and help manage symptoms at home.
A treatment that takes less time may also reduce caregiver burden. A shorter visit may mean a caregiver does not need to take a full day off work. It may make transportation easier. It may reduce the physical and emotional stress of long clinic days.
However, caregivers may still need to help watch for side effects after treatment. Shorter does not mean risk-free. Patients and caregivers should ask the care team what symptoms to report and when to call.
Does This Mean IV Infusions Are Going Away?
No. IV infusions will continue to be important in cancer care. Many cancer drugs must still be given through a vein. Some patients may not be candidates for a subcutaneous version of a drug. Others may need extra monitoring or may receive several medicines during the same visit.
Also, an on-body injector is not automatically better for every patient. The best treatment method depends on the medicine, the cancer type, the treatment plan, safety needs, insurance coverage, clinic resources, and patient preference.
The approval of one wearable injector for one cancer drug does not change all cancer treatment. But it may open the door to more options in the future.
Questions Patients Should Ask Their Oncology Team
If you or a loved one has multiple myeloma and receives Sarclisa, you may want to ask whether the new subcutaneous option is appropriate.
Here are helpful questions:
“Am I currently receiving Sarclisa or isatuximab-irfc?”
“Is the subcutaneous version approved for my treatment plan?”
“Would an on-body injector be safe for me?”
“How long would my visit take compared with IV infusion?”
“Would I still need lab work before treatment?”
“What side effects should I watch for?”
“Would my insurance cover this form of treatment?”
“Would I need to stay at the clinic for monitoring?”
“Can my caregiver be present during treatment?”
It is also okay to ask, “What are the pros and cons for me personally?” That question helps your doctor explain the choice based on your exact situation.
What Side Effects Should Patients Know About?
Every cancer medicine can have side effects. The side effects of a drug may depend on the medicine itself, the other drugs used with it, and the person receiving treatment.
The FDA approval page notes common adverse reactions for subcutaneous isatuximab-irfc combinations, including upper respiratory tract infection, diarrhea, fatigue, pneumonia, and musculoskeletal pain, among others. Patients should talk with their oncology team about which symptoms are expected, which are urgent, and how to manage them.
Never assume that a shorter treatment visit means there are no side effects. Patients should still report fever, trouble breathing, swelling, rash, severe diarrhea, chest pain, confusion, or any symptom that feels serious or unusual.
Why This News Is Bigger Than One Drug
This FDA approval is about one treatment option for multiple myeloma. But the bigger story is about the future of cancer care.
Cancer treatment is becoming more personal. Doctors are not only asking, “Which drug might work?” They are also asking, “How can we make care safer, easier, and more manageable?”
That matters because quality of life matters. Time matters. Comfort matters. Caregiver stress matters. A patient’s energy matters.
A shorter treatment visit may not sound dramatic, but for someone who has spent many hours in infusion centers, it can feel meaningful.
The Bottom Line
Wearable cancer drug injectors may help reduce the time some patients spend in infusion centers. The recent FDA approval of subcutaneous isatuximab-irfc with an on-body delivery system for multiple myeloma is an important step toward less burdensome cancer treatment.
This option is not for everyone, and patients should not change treatment without speaking to their oncology team. But for some people with multiple myeloma, it may offer a more convenient way to receive an important cancer medicine.
Cancer care should focus on treating the disease and supporting the person. Less time in the infusion chair may mean more time for rest, family, work, and life outside the clinic.
References
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
US FDA approves Sanofi's wearable injector form of blood cancer drug
For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.
This blog was reviewed by Dr. Sourabh Kharait.
This blog is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making any changes to your treatment plan, hydration strategies, or diet. The information provided here is based on general insights and may not apply to individual circumstances.
